scholarly journals Chronic Migraine

Migraine ◽  
2020 ◽  
Author(s):  
Diana Obelieniene ◽  
Ruta Pestininkaite ◽  
Daiva Rastenyte
Keyword(s):  
Valproic Acid ◽  
Chronic Migraine ◽  
Migraine Headache ◽  
Treatment Options ◽  
Migraine Treatment ◽  
Evidence Based ◽  
New Developments ◽  
Onabotulinumtoxin A ◽  
History Of ◽  
Over Time

Chronic migraine as a disease was initially recognized in patients with a large burden of disability from frequent headaches and a history of prior migraines. Over time, this observation was operationalized into multiple diagnostic criteria with requirements for frequent headache days, typically 15 or more, which, on at least 8 days in a month, have the features of migraine headache. Chronic migraine affects 1–2% of the general population, and about 8% of patients with migraine. Understanding disease mechanisms still remains a challenge. Inflammation and central sensitization play significant role in the evolutive mechanisms of chronic migraine. Treatment of this condition should primarily focus on the prevention. The currently available evidence-based prophylactic treatment options are topiramate, valproic acid, onabotulinumtoxin A and recently developed promising anti-CGRP monoclonal antibodies. Chronic migraine research is a dynamic and rapidly advancing area. New developments in this field have the potential to improve the diagnosis, to provide more personalized treatments and to reduce burden of disability.

scholarly journals Migraine Headache : An Overview

2010 ◽  
Vol 23 (1) ◽  
pp. 114-119
Author(s):  
ASM Hasan ◽  
Iftekhar Mahmood ◽  
MR Islam ◽  
MSI Khan ◽  
SM Ali ◽  
...  
Keyword(s):  
Migraine Headache ◽  
Botulinum Toxin Type A ◽  
Antihypertensive Agents ◽  
Opioid Analgesics ◽  
The Elderly ◽  
Botulinum Toxin Type ◽  
The United States ◽  
Treatment Modalities ◽  
Migraine Treatment ◽  
History Of

The history of headache can be traced almost to the beginning of the history of humankind. Among the many causes of it, migraine headache is a debilitating disorder affecting millions of people in the United States and worldwide. The diagnosis of migraine can significantly affect quality of life, health care costs and daily productivity. Hundreds of trials and many guidelines have documented various approaches to migraine management, whether via acute treatment or chronic migraine prophylaxis. Acute or abortive migraine management encompasses specific and nonspecific migraine therapeutics including non-opioid and opioid analgesics, triptans and ergotamines. Prophylactic migraine management data span the pharmacological spectrum from antiepileptic and antihypertensive agents to botulinum toxin type A. Special considerations for migraine management also must be applied in various populations including children, pregnant women and the elderly. Although hundreds of clinical trials are available regarding migraine treatment modalities, this review serves as an introduction to current accepted therapeutics for migraine treatment and an overview of pharmacological prophylaxis in the modern management of migraine. TAJ 2010; 23(1): 114-119

scholarly journals Current and emerging evidence-based treatment options in chronic migraine: a narrative review

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Elio Clemente Agostoni ◽  
◽  
Piero Barbanti ◽  
Paolo Calabresi ◽  
Bruno Colombo ◽  
...  
Keyword(s):  
Chronic Migraine ◽  
Treatment Options ◽  
Narrative Review ◽  
Evidence Based ◽  
Evidence Based Treatment

Cognitive behavioral therapy for chronic migraine

2017 ◽  
Vol 41 (S1) ◽  
pp. s500-s500 ◽  
Author(s):  
O. Onur ◽  
D.H. Ertem ◽  
D. Uludüz ◽  
Ç. Karşıdağ
Keyword(s):  
Chronic Migraine ◽  
Psychological Treatment ◽  
Treatment Options ◽  
Depression Scale ◽  
Migraine Treatment ◽  
Hamilton Depression Scale ◽  
Post Traumatic Stress ◽  
Current Standard ◽  
Significant Difference ◽  
Hamilton Anxiety

AimAlthough current standard treatment for migraine headache is medication, high levels of psychological comorbidity has led to migraine influencing by cognitive, emotional and environmental factors, as well as biological. Viewing migraine in a biopsychosocial framework introduces the possible utilisation of psychological treatment options, such as cognitive behavioural therapy (CBT). The aim of this study was to evaluate the efficacy of CBT for chronic migraine.MethodologyThirty-five participants diagnosed as chronic migraine were recruited from Headache Clinic. According to inclusion criteria 14 participants, underwent bi-weekly lasting 30 minutes CBT sessions for 6 months, were administered Hamilton Anxiety Scale, Hamilton Depression Scale, Visual Analog Scale (VAS) and the Migraine Disability Assessment Scale (MİDAS) before and after CBT.FindingsNine of the participants were female and 5 male. Mean age of group was 34.35 ± 8.17. Duration of illness was 13.07 ± 7.18 and 12 of participants had the history of a psychiatry illness whose diagnoses were depression (7), anxiety disorder (4) and post-traumatic stress disorder (1). Nine of the patients had prophylactic migraine treatment. There were statistically significant difference in Hamilton Depression scores between before CBT (29.07 ± 7.74) and after CBT (14.21 ± 7.7); in Hamilton Anxiety scores before CBT (26.8 ± 11.7) and after CBT (11.7 ± 2.6); in VAS scores before CBT (8.07± 0.91) and after CBT (3.71 ± 1.32); in frequency of migraine attacks between before CBT (10.85 ± 3.50 day) and after CBT (4.92 ± 2.70 day) and in MİDAS before CBT (55.5 ± 20.4) and after CBT (20.12 ± 16.6) (P < 0.05).ConclusionCBT might reduce the severity of symptoms in migraine patients especially with the comorbidity of psychiatric illness.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Clinician-Patient Dialogue About Preventive Chronic Migraine Treatment

2020 ◽  
Vol 11 ◽  
pp. 215013272095993
Author(s):  
Andrew M. Blumenfeld
Keyword(s):  
Chronic Migraine ◽  
Treatment Approach ◽  
Treatment Options ◽  
Correct Diagnosis ◽  
Severe Form ◽  
Migraine Treatment ◽  
Appropriate Treatment ◽  
The Individual ◽  
Practical Recommendations

Many new medications for the treatment of migraine are now available on the market. In the current evolving migraine treatment landscape, an individualized treatment approach is needed. This review provides practical recommendations on how to obtain a correct diagnosis and then engage in a long-term partnership with patients with the most severe form of migraine: chronic migraine (CM). Given the need to effectively treat this complex neurological disease, clinicians in primary care, general neurologists, and headache specialists are at the forefront to ease the burden of this disease for their patients. This manuscript will review how to discuss the currently available treatment options to help control migraine attacks, manage expectations, and, together with the patient, determine the most effective and appropriate treatment. The goal is to create an environment where the clinician partners with the patient in shared decision-making to choose the most effective appropriate treatment for the individual patient.

Rimegepant: acute treatment for migraine headaches

2021 ◽  
Author(s):  
Golden L Peters ◽  
Erin K Hennessey
Keyword(s):  
Migraine Headache ◽  
Acute Treatment ◽  
Treatment Options ◽  
Migraine Treatment ◽  
Acute Migraine ◽  
The Past ◽  
Vasoactive Peptides ◽  
Migraine Headaches ◽  
Calcitonin Gene ◽  
Acute Migraine Treatment

Migraine headache treatment is quickly evolving. There have been three new acute migraine treatment options (i.e., lasmiditan, rimegepant, ubrogepant) and four new preventive migraine treatment options (i.e., erenumab, fremanezumab, galcanezumab, eptinezumab) released in the past 3 years. The new migraine treatments are focusing on pathways within the newly, better understood neurovascular hypothesis that further describes the pathophysiology of migraine headaches in more detail than before. The discovery of vasoactive peptides, such as calcitonin gene-related peptide, has led to the development of many of these migraine agents. Rimegepant is one of these newly approved agents for acute migraine treatment in adults with or without aura. Rimegepant has been found to decrease pain and symptoms associated with migraine attacks and is generally well-tolerated.

Headache and psychiatry

2020 ◽  
pp. 475-483
Author(s):  
Maurizio Pompili ◽  
Dorian A. Lamis ◽  
Frank Andrasik ◽  
Paolo Martelletti
Keyword(s):  
Mental Illness ◽  
Chronic Migraine ◽  
Migraine With Aura ◽  
Migraine Headache ◽  
Migraine Without Aura ◽  
Psychiatric Comorbidity ◽  
Somatic Symptoms ◽  
Migraine Aura ◽  
Migraine Headaches ◽  
History Of

Patients suffering from different types of headache typically complain of numerous associated symptoms (e.g. behavioural and somatic), which may be partially related to psychiatric comorbidity. Somatic symptoms have been demonstrated to be more common in patients with chronic migraine, especially for severe headaches with accompanying depression or anxiety. Moreover, chronic migraine may be considered as distinct from an episodic type of migraine with aura, migraine without aura, and migraine aura without headache (without a history of characteristic migraine headaches). Accordingly, the present chapter explores the prevalence and impact of mental illness in patients diagnosed with migraine headache.

Managing Our First Breaths: A Reflection on the Past Several Decades of Neonatal Pulmonary Therapy

2002 ◽  
Vol 21 (5) ◽  
pp. 13-20 ◽  
Author(s):  
Suzanne Touch ◽  
Thomas Shaffer ◽  
Jay Greenspan
Keyword(s):  
Treatment Options ◽  
Significant Morbidity ◽  
Term Infants ◽  
Future Directions ◽  
New Developments ◽  
Adjuvant Therapies ◽  
The Past ◽  
History Of ◽  
Treatment Plans ◽  
Respiratory Drugs

Lung disease has been a leading cause of significant morbidity and mortality since neonates first drew breath. Over the past few decades, many treatment options have evolved to aid us in our ability to support neonatal breathing. The history of neonatal pulmonary care, both its successes and controversies, can teach us a great deal about the future of this dynamic field. As new developments occur, we constantly modify the therapies we offer to preterm and term infants. Understanding traditional therapeutic options and knowing what may be on the horizon can help caregivers to better match treatment plans with individual infants. This article reviews advances in mechanical ventilation, adjuvant therapies, and respiratory drugs through the past few decades and speculates on future directions in this field.

scholarly journals How Many Trigger Fingers Resolve Spontaneously Without Any Treatment?

2017 ◽  
Vol 26 (1) ◽  
pp. 52-54 ◽  
Author(s):  
Daniel McKee ◽  
Jan Lalonde ◽  
Don Lalonde
Keyword(s):  
Natural History ◽  
Active Treatment ◽  
Treatment Options ◽  
Case Series ◽  
Spontaneous Resolution ◽  
Trigger Finger ◽  
Consecutive Case ◽  
Time Period ◽  
History Of ◽  
Over Time

Introduction: There is very little information in the literature evaluating the natural history of adult trigger fingers and their rate of spontaneous resolution over time. Methods: A consecutive case series of patients with trigger finger was generated. For each patient, we recorded whether the patient’s disease resolved from either no treatment versus active treatment options and over what time period. Results: Three hundred forty-three patients with trigger finger were included in the study. Fifty-two percent of patients resolved without any treatment whatsoever after waiting a mean (and median) of 8 months from initial consultation. The thumb was the most frequent digit to resolve without treatment (72%). Conclusions: We found that just over half of patients with trigger fingers who are referred to our office resolve spontaneously without any intervention.

Prophylactic Effect of Memantine on Chronic Migraine Headache

2019 ◽  
Vol 16 (12) ◽  
pp. 5327-5331
Author(s):  
Davood Kashipazha ◽  
Sahereh Emadi
Keyword(s):  
Chronic Migraine ◽  
Migraine Headache ◽  
Migraine Treatment ◽  
Prophylactic Effect ◽  
Migraine Headaches ◽  
Treatment And Prevention ◽  
Significant Difference ◽  
High Prevalence ◽  
The Mean

Given the high prevalence of migraine treatment failure and resistance to existing drugs and side effects of drugs, finding alternative therapies for refractory patients or chronic migraine is essential. Fifty four patients with migraine headaches were stochastic classified to the 2 groups: placebo and memantine. In first one, memantine is managed at a dose of 20 mg in a day, that enhanced 4 weeks to this dose, and in second group placebo was given. The severity, duration, incapacity, and frequency of migraine headache attacks were recorded at the starting of the research, and the end of first, second, third and fourth months of the study. The mean of VAS score did not have a significant difference at the beginning of the study and at the end of the first month, however here was a significant decrease in the memantine group, during the end of second, third and fourth. After 4 months of behaving, MIDAS score were 22.44±10.62 in the memantine group, when in the placebo group, this was 14.47±1.79 (p <0.0001). The outcomes shows the role of memantine on the treatment and prevention of chronic migraine headaches. In addition, the migraine headaches incidence is mainly decreased in the memantine group in comparison to placebo at the end of the research.

Comparative Analysis: The State of Colorado Study, Part II

2004 ◽  
Vol 9 (2) ◽  
pp. 1-16
Author(s):  
Christopher R. Brigham ◽  
Kathryn Mueller ◽  
Douglas Van Zet ◽  
Debra J. Northrup ◽  
Edward B. Whitney ◽  
...  
Keyword(s):  
Daily Living ◽  
Scientific Evidence ◽  
Pain Syndrome ◽  
Evidence Based ◽  
Clinical Assessments ◽  
Physician Judgment ◽  
History Of ◽  
Key Terms ◽  
Causation Analysis ◽  
Work Interference

Abstract [Continued from the January/February 2004 issue of The Guides Newsletter.] To understand discrepancies in reviewers’ ratings of impairments based on different editions of the AMA Guides to the Evaluation of Permanent Impairment (AMA Guides), users can usefully study the history of the revisions as successive editions attempted to provide a comprehensive, valid, reliable, unbiased, and evidence-based system. Some shortcomings of earlier editions have been addressed in the AMA Guides, Fifth Edition, but problems remain with each edition, largely because of the limited scientific evidence available. In the context of the history of the different editions of the AMA Guides and their development, the authors discuss and contextualize a number of key terms and principles including the following: definitions of impairment and normal; activities of daily living; maximum medical improvement; impairment percentages; conversion of regional impairments; combining impairments; pain and other subjective complaints; physician judgment; and causation analysis; finally, the authors note that impairment is not synonymous with disability or work interference. The AMA Guides, Fifth Edition, contrasts impairment evaluations and independent medical evaluations (this was not done in previous editions) and discusses impairment evaluations, rules for evaluations, and report standards. Upper extremity and lower extremity impairment evaluations are discussed in terms of clinical assessments and rating processes, analyzing important changes between editions and problematic areas (eg, complex regional pain syndrome).

Sign in / Sign up

Export Citation Format

Share Document